Prostate Cell News Volume 15.23 | Oct 4 2024

    0
    84







    2024-10-04 | PCN 15.23



    Prostate Cell News by STEMCELL Technologies
    Vol. 15.23 – 4 October, 2024
    TOP STORY

    Heterogeneous Genetic Architectures of Prostate Cancer Susceptibility in Sub-Saharan Africa

    The authors used genomic data from 3,963 cases and 3,509 controls from Ghana, Nigeria, Senegal, South Africa and Uganda to infer ancestry-specific genetic architectures and fine-map disease associations.
    [Nature Genetics]

    Abstract

    October 2024 Science Events
    PUBLICATIONSListed by the impact factor of the journal

    A Novel Targeted Microtubules Transformable Nanopeptide System Yields Strong Anti-Prostate Cancer Effects by Suppressing Nuclear Translocation of Androgen Receptors

    Scientists developed the targeted microtubules transformable nanopeptide system. This system was designed to disrupt microtubule structure and function through dual-targeting of prostate-specific membrane antigen and β-tubulin.
    [Advanced Materials]

    Abstract

    Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors

    Using isogenic prostate cancer models generated by CRISPR/Cas9-mediated inactivation of CDK12, the authors conducted a chemical library screen of ~1800 FDA-approved drugs. They inhibited cyclin K and CDK13 and evaluated the effects on poly ADP-ribose polymerase inhibitor sensitivity.
    [Clinical Cancer Research]

    Abstract

    Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects

    Scientists conducted a Phase II, multi-center, single-arm trial evaluating nivolumab in post-docetaxel metastatic castration-resistant prostate cancer patients. DNA repair defects were assessed using circulating tumor DNA.
    [Clinical Cancer Research]

    Abstract

    Proteomic and Phosphoproteomic Landscape of Localized Prostate Cancer Unveils Distinct Molecular Subtypes and Insights into Precision Therapeutics

    Investigators identified three distinct proteomic subtypes with significant difference in both molecular features and clinical prognosis.
    [Proceedings of The National Academy of Sciences of The United States of America]

    Abstract

    Integrated Multi-Omics Assessment of Lineage Plasticity in a Prostate Cancer Patient with Brain and Dural Metastases

    Researchers described a patient with two treatment-emergent metastatic lesions, one to the brain with neuroendocrine prostate cancer histology and one to the dural membrane of adenocarcinoma histology.
    [NPJ Precision Oncology]

    Full Article

    Nuclear Receptor TLX Functions to Promote Cancer Stemness and EMT in Prostate Cancer via Its Direct Transactivation of CD44 and Stem Cell-Regulatory Transcription Factors

    Prostate cancer stem cells were isolated from various prostate cancer cell lines and clinical tumour tissues using multiple methods for various in vitro and in vivo oncogenic growth analyses.
    [British Journal of Cancer]

    AbstractGraphical Abstract

    Evaluating 4Kscore’s Role in Predicting Progression on Active Surveillance for Prostate Cancer Independently of Clinical Information and PIRADS Score

    This was a single-institution, single-arm, non-therapeutic, interventional trial of 166 men with biopsy-confirmed prostate cancer enrolled between 2014–2020.
    [Prostate Cancer and Prostatic Diseases]

    Abstract

    PDIA2 Is Associated with the Prognosis of Prostate Cancer, and Downregulation of PDIA2 Delays the Progression of Prostate Cancer Cells

    Patients with prostate cancer (PC) who express PDIA2 high in particular have a bad prognosis in terms of progression-free survival. The upregulation of PDIA2 expression in PC patients was accompanied by higher Gleason scores, advanced tumor staging, lymph node metastasis, and elevated PSA levels.
    [Scientific Reports]

    Full Article

    Download these free lab templates to increase your efficiency as a life science researcher.
    REVIEWS

    Biological Functions and Molecular Mechanisms of LINC01116 in Cancer

    Scientists summarize the current evidence regarding the biological functions and molecular mechanisms of LINC01116 in the progression of cancer, providing theoretical references for LINC01116-related cancer treatment in the future.
    [Heliyon]

    Full Article
    INDUSTRY AND POLICY NEWS

    UK Black Men Are 2.5 Times As Likely To Die From Prostate Cancer

    A “dangerously biased” combination of social factors and inadequate research is raising Black men’s already-heightened risk of developing prostate cancer, a UK charity has stated
    [Forbes]

    Press Release

    Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

    Curium announced that it has entered into a strategic partnership with PDRadiopharma, Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.
    [Curium]

    Press Release

    The
    Pharma& Group Enters Into an Exclusive Promotional Agreement With Tolmar, Inc. to Promote Rubraca® (Rucaparib) in the US for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    pharmaand GmbH and Tolmar, Inc. announced an exclusive agreement for Tolmar to promote Rubraca in the US for the treatment of metastatic castration-resistant prostate cancer.
    [pharmaand GmbH (PR Newswire)]

    Press Release
    FEATURED EVENT

    Cell and Gene 2024

    November 6-8, 2024
    London, England, United Kongdom

    > See All Events

    JOB OPPORTUNITIES

    Cleaner – Tissue Culture

    Wellcome Trust – Cambridge, England, United Kingdom

    Laboratory Head – Translational Cancer Research

    Northwell Health – Manhasset, New York, United States

    Leader – Prostate Cancer Program

    Fred Hutch Cancer Center – Seattle, Washington, United States

    Staff Bioinformatician – Prostate and Bladder Cancer

    Vancouver Prostate Centre – Vancouver, British Columbia, Canada

    Postdoctoral Research Fellow – Treatment Resistance in Prostate Cancer

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs


    Submit an article, publication, job or event
    Brought to you by

    stemcell-logo-for newsletter-2